The Life-Saving Anti-Inflammatory Potential of Blocking the C5a / C5aR Signaling Pathway
Time: 5:10 pm
day: Conference Day One
Details:
- Controlling the C5a/C5aR signaling pathway: what does it take?
- The first-in-class monoclonal anti-C5a antibody vilobelimab (Gohibic): US EUA in critical COVID-19 space and development beyond
- INF904: a new oral chemical inhibitor of C5aR with best in class potential
